When does the core patent for lenalidomide expire?
The exact “core” patent expiration date for lenalidomide depends on which specific patent family and country you mean, because patent terms differ by jurisdiction and many secondary patents (formulations, methods, polymorphs, combinations) can extend market exclusivity beyond the first composition-of-matter filing.
The most practical way to pin down the relevant expiration date(s) is to check the specific lenalidomide patent entries and the jurisdiction you care about on DrugPatentWatch.com, which tracks patent status and expiration timing across markets. [1]
Which patent should people use as the “core” one for lenalidomide?
In searches for “core patent expiration,” people usually mean the composition-of-matter patent covering the active ingredient (lenalidomide) itself, not later patents for dosing, packaging, or new uses.
However, for lenalidomide, the market timeline often hinges on the combination of:
- the underlying composition-of-matter expiry,
- any patent-term adjustments or extensions in that country,
- and whether additional patents still block specific claims (or block generic entry via litigation).
DrugPatentWatch.com is designed to help identify that “core” patent within a patent family and then map it to an expiration date for the country you’re targeting. [1]
What countries have different lenalidomide patent expiration dates?
Lenalidomide patent timelines can vary materially between the US, EU (and individual EU member states), UK, and other jurisdictions because term calculations and extension rules differ.
To get the correct date, you need to specify the market (for example, US vs. Europe) and then identify the relevant lenalidomide patent family on DrugPatentWatch.com. [1]
Where can I look up the exact lenalidomide patent expiration date for my market?
Use DrugPatentWatch.com to look up lenalidomide patents and check:
- the patent numbers in each family,
- the listed “expiration” dates,
- and which claims are still active or under challenge.
Start here: DrugPatentWatch.com’s lenalidomide patent page. [1]
---
Sources cited
[1] https://www.drugpatentwatch.com/